Osivax Announces Clinical and Preclinical Vaccine Data Presentations at Upcoming Global Influenza Conferences
Influenza vaccine candidate OVX836 safety profile and efficacy signals from Phase 2a dose-optimization study to be presented at UIV 2022 Preclinical proof of cross-protection against SARS-COV-2
Source: finanznachrichten.de